Release Date: November 25, 2025
Expiration Date: November 25, 2026
Activity Overview
Rapid and thorough biomarker testing is crucial to optimizing individual treatment plans for patients with non–small cell lung cancer (NSCLC). Emerging targeted therapies are improving outcomes for patients whose tumors harbor actionable mutations.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from an Association of Cancer Care Centers virtual webcast series on current and emerging therapies in NSCLC. This unique and engaging multimedia activity is ideal for the community-based clinician. It focuses on biomarker testing and clinical trial data of targeted agents. The program is designed for those who did not attend the live meeting and to help reinforce learning for those who did.
Target Audience
This educational program is primarily directed toward community-based oncologists involved in the treatment of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate key biomarkers and their role in guiding targeted therapy selection in non-small cell lung cancer (NSCLC)
- Implement molecular testing strategies to identify actionable mutations in clinical practice
- Apply clinical trial evidence supporting the efficacy and safety of targeted therapies in NSCLC to manage patients with NSCLC with actionable mutations optimally
- Identify optimal strategies to manage adverse events associated with novel targeted therapies in NSCLC
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here